LADENBURG THALM/SH SH Begins Coverage on Calidi Biotherapeutics (NYSEAMERICAN:CLDI)
LADENBURG THALM/SH SH assumed coverage on shares of Calidi Biotherapeutics (NYSEAMERICAN:CLDI – Free Report) in a research report report published on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $1.00 target price on the stock. Several other brokerages have also recently issued reports on CLDI. Robert W. Baird dropped their target […]
More Stories
Rapper Sean “Diddy” Combs Accused of Sexual Assault and Trafficking
A lawsuit has been filed against the rapper, Sean ‘Diddy’ Combs for sexual assault and sex trafficking. The accusation, which...
EQT Holdings Limited (ASX:EQT) Insider David Sedgwick Purchases 1,109 Shares
EQT Holdings Limited (ASX:EQT – Get Free Report) insider David Sedgwick bought 1,109 shares of the business’s stock in a...
Insider Selling: Tilly’s, Inc. (NYSE:TLYS) Director Sells $28,314.00 in Stock
Tilly’s, Inc. (NYSE:TLYS – Get Free Report) Director Seth R. Johnson sold 5,148 shares of the company’s stock in a...
Simulations Plus (NASDAQ:SLP) Releases FY24 Earnings Guidance
Simulations Plus (NASDAQ:SLP – Get Free Report) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of...
Canopy Growth Co. (NASDAQ:CGC) Director Sells $12,711.03 in Stock
Canopy Growth Co. (NASDAQ:CGC – Get Free Report) Director Theresa Yanofsky sold 1,983 shares of the stock in a transaction...
Simon Property Group, Inc. (NYSE:SPG) Director Buys $72,982.62 in Stock
Simon Property Group, Inc. (NYSE:SPG – Get Free Report) Director Reuben S. Leibowitz purchased 486 shares of the company’s stock...